Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tourmaline Bio ( (TRML) ) has provided an announcement.
On September 8, 2025, Tourmaline Bio entered into a merger agreement with Novartis AG, where Novartis will acquire Tourmaline for $48.00 per share, valuing the transaction at approximately $1.4 billion. This acquisition, approved by both companies’ boards, highlights the potential of Tourmaline’s pacibekitug as a breakthrough treatment for cardiovascular diseases, with the transaction expected to close in the fourth quarter of 2025.
The most recent analyst rating on (TRML) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Tourmaline Bio stock, see the TRML Stock Forecast page.
Spark’s Take on TRML Stock
According to Spark, TipRanks’ AI Analyst, TRML is a Neutral.
Tourmaline Bio’s overall stock score reflects substantial financial and profitability challenges. While the technical indicators suggest some positive momentum, the negative P/E ratio and lack of dividend yield indicate valuation concerns. The strong equity position is a positive, but is overshadowed by the company’s significant cash flow issues and lack of revenue growth.
To see Spark’s full report on TRML stock, click here.
More about Tourmaline Bio
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines for inflammatory and immune diseases. Its lead product, pacibekitug, is a long-acting, fully-human, anti-IL-6 monoclonal antibody aimed at treating cardiovascular diseases.
Average Trading Volume: 213,946
Technical Sentiment Signal: Buy
Current Market Cap: $687M
See more insights into TRML stock on TipRanks’ Stock Analysis page.